News coverage about Pain Therapeutics (NASDAQ:PTIE) has been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pain Therapeutics earned a daily sentiment score of 0.04 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 48.4492649893933 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
PTIE traded down $0.11 on Tuesday, hitting $1.11. The company had a trading volume of 223,000 shares, compared to its average volume of 393,317. The firm has a market cap of $7.89 million, a P/E ratio of -0.61 and a beta of 2.72. Pain Therapeutics has a 1 year low of $1.02 and a 1 year high of $12.80.
Pain Therapeutics (NASDAQ:PTIE) last released its earnings results on Thursday, July 26th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.29.
Pain Therapeutics Company Profile
Pain Therapeutics, Inc develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease.
Featured Article: What is the NASDAQ Stock Market?
Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.